Sildigra Softgel
$ 42,00 – $ 317,00Price range: $ 42,00 through $ 317,00
Sinemet
$ 46,00 – $ 623,00Price range: $ 46,00 through $ 623,00
Silvitra
$ 96,00 – $ 498,00Price range: $ 96,00 through $ 498,00
Silvitra is an innovative combination therapy specifically formulated to treat erectile dysfunction in men. By integrating the power of Sildenafil and Vardenafil, this medication enhances the physiological response to sexual stimulation. The active components work together to relax smooth muscles and increase blood flow to the pelvic region for a firm and lasting erection. This dual-action formula provides a reliable solution for improving sexual performance and restoring confidence in intimate moments. Each dose is designed to offer a consistent and effective experience, supporting overall sexual health and satisfaction.
Active substance: Sildenafil, Vardenafil
SKU:
Silvitra
Category: Erectile Dysfunction
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Silvitra belongs to a class of pharmacological agents known as phosphodiesterase type 5 (PDE5) inhibitors, combined to modify vascular smooth muscle tone. The preparation is formulated with active ingredients that alter hemodynamic responses in specific target tissues under physiological stimulation.
This medication contains sildenafil citrate and vardenafil hydrochloride, which act on the cyclic guanosine monophosphate (cGMP) signaling pathway. In the United States, medications within this pharmacological category are dispensed in accordance with applicable federal and state regulations.
| Parameter | Specification |
|---|---|
| Drug name | Silvitra |
| Active ingredients | Sildenafil citrate, Vardenafil hydrochloride |
| Therapeutic class | Phosphodiesterase type 5 (PDE5) inhibitors |
| Route of administration | Oral |
| Primary purpose | Treatment of erectile dysfunction in adult males |
| Storage | Store at 20°C to 25°C (68°F to 77°F) |
Pharmacological Overview and Clinical Indications
Main uses
Silvitra is indicated primarily for the management of erectile dysfunction (ED) in adult males. Erectile dysfunction is defined as the persistent inability to attain or maintain a penile erection sufficient for satisfactory sexual performance. The active components, sildenafil and vardenafil, facilitate local vascular relaxation within erectile tissues. Any off-label application of this combination formulation for vascular conditions, such as pulmonary arterial hypertension, is considered non-standard and off-label, requiring rigorous clinical justification and individualized physician oversight. The medication does not increase sexual desire or correct underlying endocrine abnormalities; its therapeutic utility relies entirely on intact neurological and vascular pathways during organic stimulation.
How the drug works
The mechanism of action of Silvitra relies on the selective inhibition of phosphodiesterase type 5 (PDE5) enzymes located within the smooth muscle cells of the corpus cavernosum. Under physiological sexual stimulation, nitric oxide (NO) is released from local nerve endings and endothelial cells. Nitric oxide stimulates the enzyme guanylate cyclase, increasing synthesized levels of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels induce smooth muscle relaxation and arterial dilation, permitting increased blood flow into the penile tissue. Sildenafil and vardenafil prevent PDE5 from degrading cGMP, thereby sustaining arterial vasodilation. Without preceding sexual stimulation to initiate endogenous nitric oxide release, the pharmacological pathway remains inactive.
What happens in the body
Following oral administration, both sildenafil citrate and vardenafil hydrochloride undergo rapid systemic absorption through the gastrointestinal tract. Peak plasma concentrations of sildenafil are typically reached within 30 to 120 minutes, while vardenafil reaches peak concentrations within approximately 30 to 120 minutes post-dose under fasting conditions. Both active compounds exhibit high plasma protein binding, primarily to serum albumin. Hepatic metabolism occurs predominantly via the cytochrome P450 enzyme system, specifically the CYP3A4 pathway, with secondary contributions from CYP2C9 isoenzymes. Metabolites are excreted primarily in the feces (approximately 80%) and to a lesser extent in urine (approximately 13% to 15%). The terminal elimination half-life for both components ranges between 3 to 5 hours in healthy adult subjects.
Dosing schedule
Dosing schedules for Silvitra must be established by a qualified healthcare provider based on individual clinical evaluation, patient tolerance, and underlying systemic health. The standard protocol involves taking one tablet orally with water approximately 30 to 60 minutes prior to anticipated sexual activity. The tablet should be swallowed whole without chewing, splitting, or crushing. Patients are advised not to exceed more than one dose within a 24-hour period. Adjustments to the dosing schedule may be required for geriatric patients or individuals with hepatic or renal impairment. Consuming heavy or high-fat meals prior to ingestion may delay gastrointestinal absorption and delay peak therapeutic plasma levels.
First days of treatment
Upon initiating treatment with Silvitra, patients may experience mild, transient vasodilation-related systemic effects. Initial responses can vary based on underlying vascular health, metabolic clearance rates, and dietary factors. It is common to observe subtle changes in facial temperature or mild nasal congestive symptoms during initial administration instances. Clinical response should be evaluated across multiple uses before dosage modifications are considered. If consistent therapeutic benefit is not achieved or if adverse physiological events occur, consultation with a healthcare provider is necessary to evaluate treatment parameters.
Safety Profile, Interactions, and FAQ
Adverse reactions
Adverse reactions associated with Silvitra are predominantly linked to its systemic vasodilatory properties. The most frequently reported adverse effects include headache, facial flushing, nasal congestion, dyspepsia, and mild dizziness. Visual disturbances, such as transient blue-tinted vision (cyanopsia), altered light perception, or blurred vision, can occur due to secondary inhibition of PDE6 enzymes in the retina. Musculoskeletal reactions, including back pain and myalgia, have also been documented. Less common but severe adverse events include sudden decrease or loss of hearing, priapism (a prolonged and painful erection lasting more than four hours), and severe hypotension. Patients experiencing persistent or severe adverse symptoms must discontinue the medication and consult a medical practitioner.
Important precautions
Prior to prescribing Silvitra, a comprehensive cardiovascular evaluation must be performed, as sexual activity carries an inherent cardiac risk for patients with preexisting cardiovascular disease. Silvitra is contraindicated in individuals with severe hepatic impairment, end-stage renal disease requiring dialysis, resting hypotension (blood pressure below 90/50 mmHg), recent stroke, or recent myocardial infarction. Special caution is required in patients with anatomical penile deformities (such as Peyronie’s disease) or conditions predisposing to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). The safety and efficacy of Silvitra have not been established in pediatric populations or pregnant females. Geriatric patients may display reduced drug clearance, necessitating clinical monitoring.
Compatibility with other medicines
Silvitra exhibits significant drug interaction potential. The concurrent administration of Silvitra with organic nitrates (such as nitroglycerin, isosorbide mononitrate, or isosorbide dinitrate) or nitric oxide donors is strictly contraindicated, as it can cause profound, life-threatening hypotension. Co-administration with alpha-blockers (such as tamsulosin or doxazosin) prescribed for hypertension or benign prostatic hyperplasia requires clinical caution due to additive blood pressure-lowering effects. Potent cytochrome P450 3A4 inhibitors (including ketoconazole, itraconazole, ritonavir, and erythromycin) substantially increase systemic exposure to sildenafil and vardenafil, elevating the risk of adverse reactions. Conversely, CYP3A4 inducers (such as rifampin) may reduce plasma drug concentrations, decreasing clinical efficacy.
What to avoid while taking it
Patients receiving Silvitra should avoid high-fat meals prior to dose administration, as elevated lipid levels in the stomach can delay gastric emptying and slow drug absorption, resulting in a delayed onset of action. Concurrent consumption of alcohol should be limited or avoided. Alcohol acts as a systemic vasodilator and central nervous system depressant; combining it with PDE5 inhibitors increases the likelihood of orthostatic hypotension, dizziness, syncope, and tachycardia. Furthermore, grapefruit juice must be avoided, as it inhibits intestinal CYP3A4 enzymes, potentially leading to elevated blood levels of the active compounds and unpredictable toxicity.
Red flags
Immediate emergency medical intervention is required if specific severe adverse events occur during or after taking Silvitra. A key medical emergency is priapism, defined as an erection persisting longer than four hours, which can cause permanent erectile tissue damage if untreated. Sudden vision impairment or sudden loss of vision in one or both eyes (potentially indicative of non-arteritic anterior ischemic optic neuropathy, or NAION) warrants immediate drug cessation and emergency evaluation. Additionally, patients experiencing chest pain, severe dizziness, syncope, or sudden hearing loss should seek emergency medical care immediately.
Storage and expiration
Silvitra tablets should be stored in their original packaging at room temperature, ideally between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). The medication must be kept protected from direct light, excessive heat, and moisture. Store the product in a secure location out of the reach of children and domestic pets. Expired preparations or unused tablets should be disposed of in accordance with local pharmaceutical waste protocols and federal guidelines; flushing down toilets or household drains is discouraged.
What should be done if a scheduled dose of Silvitra is missed?
Because Silvitra is intended for use on an as-needed basis prior to sexual activity, routine daily administration schedules are generally not employed. If a healthcare provider has recommended a specific dosing schedule and a dose is missed, take the missed dose as soon as remembered, provided the next scheduled dose is not imminent. Patients must never take two doses simultaneously or double up to make up for a missed dose.
Is it safe to drive or operate machinery after taking Silvitra?
Silvitra can induce central nervous system and vascular side effects such as dizziness, lightheadedness, altered spatial awareness, or transient visual disturbances. Patients should assess their individual physiological reaction to the medication before driving, operating heavy machinery, or performing tasks requiring full alertness and visual clarity. If dizziness or visual changes occur, hazardous activities should be avoided.
How does food intake affect the onset time of this medication?
Ingesting a heavy or high-fat meal immediately before taking Silvitra significantly reduces the rate of gastrointestinal absorption for both active components. High lipid concentrations delay gastric emptying, which can extend the time required to reach peak plasma concentrations and delay the therapeutic onset. For consistent absorption kinetics, the medication is best taken on an empty stomach or with a light, low-fat meal.
Can Silvitra be taken concurrently with antihypertensive medications?
Combining Silvitra with antihypertensive drugs can produce additive blood pressure-lowering effects. Both PDE5 inhibitors and blood pressure medications lower vascular resistance. Patients taking antihypertensives–such as ACE inhibitors, beta-blockers, or calcium channel blockers–require thorough medical evaluation to determine whether combined therapy is clinically safe and to monitor for signs of orthostatic hypotension.
This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements.
Additional information
| Dosage |
100mg+20mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills ,120 pills ,180 pills |
| Ενεργός Ουσία | , |
Related products
Abhigra
$ 69,00 – $ 173,00Price range: $ 69,00 through $ 173,00
Active substance: Sildenafil
More Details
This product has multiple variants. The options may be chosen on the product page
Alprostadil
$ 450,00
Active substance: Alprostadil
More Details
This product has multiple variants. The options may be chosen on the product page
Apcalis SX Oral Jelly
$ 48,00 – $ 325,00Price range: $ 48,00 through $ 325,00
Active substance: Tadalafil
More Details
This product has multiple variants. The options may be chosen on the product page
Assurans
$ 50,00 – $ 70,00Price range: $ 50,00 through $ 70,00
Active substance: Sildenafil Citrate
More Details
This product has multiple variants. The options may be chosen on the product page
Aurogra
$ 49,00 – $ 219,00Price range: $ 49,00 through $ 219,00
Active substance: Sildenafil
More Details
This product has multiple variants. The options may be chosen on the product page
Avana
$ 112,00 – $ 419,00Price range: $ 112,00 through $ 419,00
Active substance: Avanafil
More Details
This product has multiple variants. The options may be chosen on the product page
Caverta
$ 135,00 – $ 248,00Price range: $ 135,00 through $ 248,00
Active substance: Sildenafil
More Details
This product has multiple variants. The options may be chosen on the product page
Cialis Jelly
$ 52,00 – $ 352,00Price range: $ 52,00 through $ 352,00
Active substance: Tadalafil
More Details
This product has multiple variants. The options may be chosen on the product page
